DNA Vaccines against Dengue Virus Type 2 Based on Truncate Envelope Protein or Its Domain III
2011

DNA Vaccines Against Dengue Virus Type 2

Sample size: 20 publication 10 minutes Evidence: high

Author Information

Author(s): Azevedo Adriana S., Yamamura Anna M. Y., Freire Marcos S., Trindade Gisela F., Bonaldo Myrna, Galler Ricardo, Alves Ada M. B.

Primary Institution: Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil

Hypothesis

Can DNA vaccines encoding the dengue virus envelope protein induce protective immune responses in mice?

Conclusion

The DNA vaccine pE1D2 provided complete protection against dengue virus, while pE2D2 offered only partial protection.

Supporting Evidence

  • All pE1D2-vaccinated mice survived challenge with dengue virus.
  • Only 10% of pE1D2-immunized mice showed clinical signs of infection after challenge.
  • Levels of neutralizing antibodies were significantly higher in pE1D2-vaccinated mice than in pE2D2-immunized animals.

Takeaway

Scientists created two types of DNA vaccines to protect mice from dengue virus. One vaccine worked really well, keeping all the mice safe, while the other one didn't work as well.

Methodology

Two DNA vaccines were constructed and tested in Balb/c mice, followed by a challenge with a lethal dose of dengue virus.

Limitations

The study used a mouse model, which may not fully replicate human responses to the vaccine.

Participant Demographics

Balb/c mice, 4 to 6 weeks old.

Statistical Information

P-Value

0.0027

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0020528

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication